Rafinlar 75mg Capsule Supplier USA | Pharmaceutical Exporter from India

Rafinlar 75mg Capsule: Precision BRAF-Inhibition for Advanced Melanoma & Targeted Oncology

Are you searching for a reliable Rafinlar 75 mg capsule exporter from India? Ernest Oncology, a specialized division of Ernest Pharmaceutical Pvt. Ltd., is a premier global supplier and bulk distributor of advanced targeted therapies. We maintain a high-authority, regulatory-compliant supply chain serving the USA, UK, Australia, and South Africa, ensuring that life-saving medications reach healthcare providers with pharmaceutical-grade integrity and efficient global logistics.

Detailed Product Overview: What is Rafinlar 75mg?

Rafinlar 75 mg is a high-potency oral capsule containing the active pharmaceutical ingredient Dabrafenib. It is a sophisticated targeted cancer therapy belonging to the class of BRAF inhibitors.

Manufactured by Novartis India Ltd., Rafinlar 75mg is precision-engineered to inhibit specific mutated proteins that drive tumor growth. For international B2B procurement, Rafinlar offers a world-class, cost-effective alternative to innovator brands (like Tafinlar), providing critical support for patients with advanced malignancies.

Primary Therapeutic Indications

Rafinlar 75 mg capsule is clinically indicated for the management of:

1. Malignant Melanoma: Treatment of patients with unresectable or metastatic melanoma with a confirmed BRAF V600 mutation.

2. Non-Small Cell Lung Cancer (NSCLC): Used in combination with Trametinib for patients with metastatic NSCLC harboring the BRAF V600E mutation.

3. Anaplastic Thyroid Cancer: Treatment of advanced or metastatic thyroid cancer with BRAF V600E mutations.

4. Solid Tumors: Indicated for adult and pediatric patients with BRAF V600E-mutated solid tumors that have progressed following prior treatment.

Mechanism of Action: How Rafinlar 75mg Works

Rafinlar (Dabrafenib) utilizes a molecular-targeted approach to arrest the progression of cancer cells:

• BRAF Protein Inhibition: It selectively targets and blocks the activity of the mutated BRAF protein (specifically V600E and V600K variants).

• Signaling Pathway Blockade: The mutated BRAF protein normally sends continuous "grow" signals to the cell. Rafinlar cuts off this signaling pathway.

• Anti-Tumor Response: By arresting the cell cycle and preventing uncontrolled multiplication, it slows or stops the growth of the tumor, often leading to tumor shrinkage in responsive patients.

Administration and Safety Guidelines

• Standard Dosage: Typically taken as 150mg (two 75mg capsules) twice daily, spaced approximately 12 hours apart.

• Empty Stomach: For optimal absorption, Rafinlar must be taken on an empty stomach—at least 1 hour before or 2 hours after a meal.

• Key Precautions:

• Pyrexia (Fever): High fever is a common side effect; patients should monitor their temperature and report spikes to their oncologist.

• Skin Health: New skin cancers (squamous cell carcinomas) can occur; regular dermatological check-ups are mandatory.

• Eye Problems: Patients should report blurred vision, eye pain, or redness immediately.

• Blood Glucose: It may cause hyperglycemia (high blood sugar), particularly in diabetic patients.

Why Source Rafinlar 75 mg from Ernest Oncology?

• Strategic Indian Exporter: Direct access to Novartis’ manufacturing excellence, ensuring 100% authenticity and competitive bulk pricing for the international market.

• Global Distribution Mastery: Expertise in navigating the regulatory and customs landscapes of the USA, UK, Australia, and South Africa.

• Bulk Supply Reliability: We specialize in large-scale exports for oncology hospitals, specialty clinics, and regional distributors, ensuring treatment continuity.

• Cold-Chain Integrity: Professional-grade storage and logistics to maintain the biochemical stability of oral targeted therapies during transit.